Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A2TSL71
Wed, 10.05.2023
SYNLAB AG
SYNLAB reports strong start to fiscal year 2023
Revenue stable at €702 million compared to prior quarter
Robust underlying organic growth of 10.0%, above the 4% forecast for FY 2023
COVID-19 testing revenue at €26 million vs. €70 million in previous quarter
Adjusted EBITDA margin at 16.9%, at mid-point of FY 2023 guidance of 16-18%
€10 millio [ … ]
Wed, 10.05.2023
SYNLAB AG
SYNLAB reports strong start to fiscal year 2023
Revenue stable at €702 million compared to prior quarter
Robust underlying organic growth of 10.0%, above the 4% forecast for FY 2023
COVID-19 testing revenue at €26 million vs. €70 million in previous quarter
Adjusted EBITDA margin at 16.9%, at mid-point of FY 2023 guidance of 16-18%
€10 millio [ … ]
Tue, 09.05.2023
SYNLAB AG
SYNLAB Holding Deutschland GmbH
Gubener Straße 39
86156 Augsburg
Germany
Press Release
SYNLAB invests in new, cutting-edge laboratory in Munich and further expands its leading position in the region
SYNLAB moves to new city centre location at Schwanthalerhöhe in Munich, increases laboratory space to 6,000 square metres and modernises [ … ]
Tue, 09.05.2023
SYNLAB AG
SYNLAB Holding Deutschland GmbH
Gubener Straße 39
86156 Augsburg
Germany
Press Release
SYNLAB invests in new, cutting-edge laboratory in Munich and further expands its leading position in the region
SYNLAB moves to new city centre location at Schwanthalerhöhe in Munich, increases laboratory space to 6,000 square metres and modernises [ … ]
Thu, 16.03.2023
SYNLAB AG
SYNLAB delivers robust underlying growth in FY 2022
Revenue at €3.25 billion exceeds the initial 2022 guidance
Robust underlying organic growth of 6.2% outperforms the guidance of 3%+
COVID-19 testing revenue at €790 million with gradual reductions in price and volume
Adjusted EBITDA of €753 million and margin at 23.2%
23 acquisitions at € [ … ]
Thu, 16.03.2023
SYNLAB AG
SYNLAB delivers robust underlying growth in FY 2022
Revenue at €3.25 billion exceeds the initial 2022 guidance
Robust underlying organic growth of 6.2% outperforms the guidance of 3%+
COVID-19 testing revenue at €790 million with gradual reductions in price and volume
Adjusted EBITDA of €753 million and margin at 23.2%
23 acquisitions at € [ … ]
Mon, 06.02.2023
SYNLAB AG
FY 2022 revenue anticipated to be around €3.25 billion, above guided amount of €3.2 billion
Expected strong underlying organic growth of around 6% (above 4% excluding the South-East London hospital outsourcing contract)
FY 2022 adjusted EBITDA margin anticipated to be around 23%, slightly below FY 2022 guidance, due to Q4 2022 one-off costs p [ … ]
Mon, 06.02.2023
SYNLAB AG
FY 2022 revenue anticipated to be around €3.25 billion, above guided amount of €3.2 billion
Expected strong underlying organic growth of around 6% (above 4% excluding the South-East London hospital outsourcing contract)
FY 2022 adjusted EBITDA margin anticipated to be around 23%, slightly below FY 2022 guidance, due to Q4 2022 one-off costs p [ … ]
Wed, 04.01.2023
SYNLAB AG
SYNLAB (FSE: SYAB), the leader in medical diagnostic services and speciality testing in Europe, has announced today that the Portuguese competition authority Autoridade da Concorrência (“AdC”) initiated proceedings against several medical diagnostic providers active in Portugal, including SYNLAB.
The AdC has assessed that two Portuguese subsidiari [ … ]
Thu, 10.11.2022
SYNLAB AG
SYNLAB reports strong underlying performance in 9M 2022, confirms 2022 guidance and releases 2023 guidance
Robust 9M 2022 performance with revenue of €2.5 billion
Strong underlying organic growth (excluding COVID-19 related revenues): +6.3% in 9M 2022 and +4.1% in Q3 2022, well above our mid-term organic growth target
COVID-19 testing revenue €72 [ … ]